Senior Director, GxP Quality Assurance
HAYA Therapeutics
Summary
Design, build, scale, and lead HAYA's phase-appropriate Quality Management System across GLP, GCP, and GMP domains to ensure continuous regulatory inspection readiness, robust vendor oversight, and clinical drug product compliance.
Job description
Purpose
Design, build, scale, and lead HAYA's phase-appropriate Quality Management System across GLP, GCP, and GMP domains to ensure continuous regulatory inspection readiness, robust vendor oversight, and clinical drug product compliance.
Accountabilities
- Establish and scale an enterprise-wide electronic Quality Management System (eQMS) across GLP, GCP, and GMP functional areas to maintain continuous audit-readiness across FDA, EMA, and other global regulatory frameworks.
- Oversee quality risk management (QRM), deviation investigations, CAPA, and Change Control workflows across cross-functional R&D, Clinical, and Manufacturing teams to resolve operational non-conformances and safeguard program timelines.
- Direct the global GxP vendor management and audit program across CDMOs, CROs, and testing laboratories to ensure strict compliance with regulatory dossiers and executed Quality Agreements.
- Lead inspection readiness initiatives and serve as the responsive quality lead for health authority interactions (PAI and BIMO) for pre-IND, CTA, BLA, and NDA submissions to secure timely clinical trial authorizations and product approvals.
- Manage computerized system validation (CSV to 21 CFR Part 11 / EU Annex 11) and data integrity (ALCOA+) frameworks across analytical, clinical, and manufacturing records to protect asset valuation and trial validity.
- Oversee batch record review, PSF preparation, and disposition pathways in collaboration with Qualified Persons (QPs) and Responsible Persons (RPs) to ensure compliant global investigational drug supply and distribution under MIA/WDA licenses.
Required Knowledge and Experience
Essential Qualifications & Technical Capabilities (Must-Haves)
- Education: Bachelor's or Master's degree in Biology, Chemistry, Pharmacy, or a related scientific discipline.
- Multi-Modality GxP Mastery: Comprehensive technical depth across GLP, GCP, and GMP regulations encompassing synthetic molecules, biologics, vaccines, and advanced human cell and tissue-based products (HCT/P / ATMPs).
- Regulatory Interpretation: Demonstrated capability interpreting and operationalizing US FDA CFRs (Parts 58, 210, 211, 312, 820, 1271, 600), ICH guidelines, EMA directives, and PMDA requirements using a risk-based, fit-for-purpose strategy.
- Inspection & Filing Track Record: Proven expertise preparing organizations for and leading successful regulatory health authority inspections (PAI, BIMO) and contributing to CMC Module 3 regulatory filings (IND/NDA/BLA/J-BLA).
- External CDMO/Vendor Governance: Advanced capability negotiating Quality Agreements, setting Quality Performance Indicators (QPIs), and conducting global audits across CDMO, CRO, and specialized testing facilities.
- Facility & Engineering Compliance: Practical knowledge overseeing sterile facility commissioning, qualification (IQ/OQ/PQ), and utility design under EU Annex 1 and FDA requirements.
Desirable Experience & Specialized Expertise (Nice-to-Haves)
- Experience providing strategic quality oversight for RNA therapeutics, oligonucleotides, or novel cellular delivery platforms.
- Demonstrated expertise conducting M&A due diligence, in/out-licensing asset reviews, and preparing companies for strategic transactions or public offerings.
Leadership Profile
The successful candidate will demonstrate:
- Autonomy & Strategic Scope: Operates with complete executive latitude for tactical and strategic decision-making, setting the enterprise quality vision and aligning priorities across corporate leadership.
- Enterprise Impact & Vision: Drives overall enterprise value by establishing robust compliance frameworks that protect IP, accelerate clinical asset milestones, and enhance corporate reputation with health authorities and investors.
- Pragmatic Problem Solving: Translates complex GxP non-conformances into structured root-cause analyses and risk-based solutions without imposing unnecessary bureaucratic friction on scientific teams.
- Cross-Functional Authority & Alignment: Bridges technical regulatory demands with , building cross-functional trust and fostering an integrated culture of quality.
Requirements
- Bachelor's or Master's degree in Biology, Chemistry, Pharmacy, or a related scientific discipline
- Comprehensive technical depth across GLP, GCP, and GMP regulations encompassing synthetic molecules, biologics, vaccines, and advanced human cell and tissue-based products (HCT/P / ATMPs)
- Demonstrated capability interpreting and operationalizing US FDA CFRs (Parts 58, 210, 211, 312, 820, 1271, 600), ICH guidelines, EMA directives, and PMDA requirements using a risk-based, fit-for-purpose strategy
- Proven expertise preparing organizations for and leading successful regulatory health authority inspections (PAI, BIMO) and contributing to CMC Module 3 regulatory filings (IND/NDA/BLA/J-BLA)
- Advanced capability negotiating Quality Agreements, setting Quality Performance Indicators (QPIs), and conducting global audits across CDMO, CRO, and specialized testing facilities
- Practical knowledge overseeing sterile facility commissioning, qualification (IQ/OQ/PQ), and utility design under EU Annex 1 and FDA requirements
Company overview
HAYA Therapeutics is a pioneering precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. Founded in 2019 and headquartered at the Biopôle life sciences park in Lausanne, Switzerland with laboratory facilities in San Diego, California, HAYA leverages its innovative cell-state modifying platform to gain novel insights into long non-coding RNAs (lncRNAs) - the 'dark genome' that comprises approximately 98% of human DNA. The company's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, a tissue and cell-specific cardiac lncRNA known to play a crucial role in heart failure and fibrosis. HAYA is advancing a pipeline of lncRNA-targeting candidates for cell-specific treatment of diseases across multiple tissues, including lungs and solid tumor microenvironments. Backed by a $65 million Series A financing led by Sofinnova Partners and Earlybird Venture Capital, and supported by strategic collaborations including a significant partnership with Eli Lilly and Company focused on obesity and metabolic diseases, HAYA represents a new frontier in programmable therapeutics that aim to reprogram disease-driving cell states back to healthy states, addressing complex diseases at their root cause rather than merely managing symptoms.